Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: High utilization of drugs with interaction potential

European Journal of Gastroenterology and Hepatology

Volumn 26, Issue 10, 2014, Pages 1073-1082

  Lauffenburger, Julie C ^a   Mayer, Christina L ^a   Hawke, Roy L ^a   Brouwer, Kim L R ^a   Fried, Michael W ^a   Farley, Joel F ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Boceprevir; Comorbidities; Drug interactions; Hepatitis C; Protease inhibitors; Telaprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TELAPREVIR; ANTIVIRUS AGENT; CYP3A PROTEIN, HUMAN; CYTOCHROME P450 3A; CYTOCHROME P450 3A INHIBITOR;

ADULT; ARTICLE; BILLING AND CLAIMS; CLINICAL TRIAL; COMORBIDITY; DATA BASE; DRUG UTILIZATION; FEMALE; HEALTH INSURANCE; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UNITED STATES; BIOTRANSFORMATION; CLINICAL PRACTICE; DRUG INTERACTION; DRUG USE; EPIDEMIOLOGY; FACTUAL DATABASE; HEPATITIS C, CHRONIC; IMMUNOLOGY; METABOLISM; MIDDLE AGED; POLYPHARMACY; RISK ASSESSMENT; RISK FACTOR;

ADULT; ANTIVIRAL AGENTS; BIOTRANSFORMATION; COMORBIDITY; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 CYP3A INHIBITORS; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG UTILIZATION REVIEW; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; POLYPHARMACY; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84927699066     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000152     Document Type: Article

References (56)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714.
2. Mühlberger N, Schawarzer R, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9:34.
3. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60:392-420.
4. Barritt AS 4th, Fried MW. Maximizing opportunities and avoiding mistakes in triple therapy for hepatitis C virus. Gastroenterology 2012; 142:1314-1323.e1.
5. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55:1620-1628.
6. Weiss J, Becker JP, Haefeli WE. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro. Int J Antimicrob Agents 2014; 43:184-188.
7. Hulskotte EG, Feng HP, Xuan F, van Zutven MG, Treitel MA, Hughes EA, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis 2013; 56:718-726.
8. Garg V, Chandorkar G, Yang Y, Adda N, McNair L, Alves K, et al. The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers. Br J Clin Pharmacol 2013; 75:431-439.
9. Hammond KP, Wolfe P, Burton JR Jr, Predhomme JA, Ellis CM, Ray ML, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr 2013; 62:67-73.
10. Kwo PY, Lawitz EJ, McCone J, Schiff ER, Vierling JM, Pound D, et al. SPRINT-1 investigators. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376:705-716.
11. Bifano M, Hwang C, Oosterhuis B, Hartstra J, Grasela D, Tiessen R, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther 2013; 18:931-940.
12. Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2013; 58:792-800.
13. van Heeswijk RP, Beumont M, Kauffman RS, Garg V. Review of drug interactions with telaprevir and antiretrovirals. Antivir Ther 2013; 18:553-560.
14. Wilby KJ, Greanya ED, Ford JA, Yoshida EM, Partovi N. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol 2012; 11:179-185.
15. Back D, Else L. The importance of drug-drug interactions in the DAA era. Dig Liver Dis 2013; 45 (Suppl 5):S343-S348.
16. Maasoumy B, Port K, Calle Serrano B, Markova AA, Sollik L, Manns MP, et al. The clinical significance of drug-drug interactions in the era of direct-acting anti-viral agents against chronic hepatitis C. Aliment Pharmacol Ther 2013; 38:1365-1372.
17. Louie KS, St Laurent S, Forssen UM, Mundy LM, Pimenta JM. The high comorbidity burden of the hepatitis C virus infected population in the United States. BMC Infect Dis 2012; 12:86.
18. El-Zayadi AR. Hepatitis C comorbidities affecting the course and response to therapy. World J Gastroenterol 2009; 15:4993-4999.
19. Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011; 173:676-682.
20. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47:1245-1251.
21. University of Liverpool HIV & Hepatitis Pharmacology Group Drug Interaction Charts. Available at: http://www.hep-druginteractions.org/Interactions.aspx. [Accessed 04 August 2013].
22. Merck & Co. Inc. Highlights of prescribing information. Whitehouse Station, NJ: Victrelis 2011; Available at: http://www.merck.com/product/usa/pi-circulars/v/victrelis/victrelis-pi.pdf. [Accessed 09 April 2014].
23. Vertex Pharmaceuticals. Highlights of prescribing information. Cambridge, MA: Incivek 2011; Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/201917lbl.pdf. [Accessed 09 April 2014].
24. Poordad F, McCone J Jr, Macon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
25. Bacon BR, Gorden SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
26. Poordad F, Lawitz E, Gordon S, Bouliere M, Vierling JM, Poynard T, et al. Concomitant medication use (drug interactions) in patients with hepatitis C genotype 1 treated with boceprevir combination therapy. San Francisco: American Society of Liver Diseases; 2011.
27. Basseri B, Yamini D, Chee G, Enayati PD, Tran T, Poordad F. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int 2010; 30:1012-1018.
28. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med 2011; 78:393-403.
29. Anglicheau D, Flamant M, Schlageter MH, Martinez F, Cassinat B, Beaune P, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003; 18:2409-2414.
30. Konishi H, Sumi M, Shibata N, Takada K, Minouchi T, Yamaji A. Influence of intravenous methylprednisolone pulse treatment on the disposition of ciclosporin and hepatic CYP3A activity in rats. J Pharm Pharmacol 2004; 56:477-483.
31. Leutscher PD, Lagging M, Buhl MR, Pederson C, Norkrans G, Langeland N, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 2010; 52:430-435.
32. Sockalingam S, Tseng A, Giguere P, Wong D. Psychiatric treatment considerations with direct acting antivirals in hepatitis C. BMC Gastroenterol 2013; 13:86.
33. Smith HS. Opioid metabolism. Mayo Clin Proc 2009; 84:613-624.
34. Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol 2013; 6:249-269.
35. Guggenheimer J, Moore PA. The therapeutic applications of and risks associated with acetaminophen use: a review and update. J Am Dent Assoc 2011; 142:38-44.
36. Kunze A, Huwyler J, Camenisch G, Gutmann H. Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters. Biochem Pharmacol 2012; 84:1096-1102.
37. Chu X, Cai X, Cui D, Tang C, Ghosal A, Chan G, et al. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos 2013; 41:668-681.
38. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics 2010; 20:38-44.
39. Lau YY, Huang Y, Frassetto L, Benet LZ. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin Pharmacol Ther 2007; 81:194-204.
40. Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006; 34:1247-1254.
41. Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 2005; 11: 2320-2326.
42. Allred AJ, Bowen CJ, Park JW, Peng B, Williams DD, Wire MB, Lee E. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers. Br J Clin Pharmacol 2011; 72:321-329.
43. Volk EL, Schneider E. Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res 2003; 63:5538-5543.
44. Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 2006; 34:738-742.
45. Polli JW, Humphreys JE, Harmon KA, Castellino S, O'Mara MJ, Olson KL, et al. The role of efflux and uptake transporters in [N-{3-chloro-4- [(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)- 2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. Drug Metab Dispos 2008; 36:695-701.
46. Yeo KR, Jamei M, Rostami-Hodjegan A. Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol 2013; 6:143-157.
47. Jamei M, Marciniak S, Feng K, Barnett A, Tucker G, Rostami-Hodjegan A. The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol 2009; 5:211-223.
48. Caccia S, Garattini S, Pasina L, Nobili A. Predicting the clinical relevance of drug interactions from pre-approval studies. Drug Saf 2009; 32:1017-1039.
49. Perkins NA, Murphy JE, Malone DC, Armstrong EP. Performance of drug-drug interaction software for personal digital assistants. Ann Pharmacother 2006; 40:850-855.
50. Stepanova M, Kanwal F, El-Serag HB, Younossi ZM. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011; 53:737-745.
51. Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatmentnaïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58:1918-1929.
52. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, doseranging trial. J Hepatol 2013; 58:663-668.
53. Li Y, Zhou J, Ramsden D, Taub ME, O'Brien D, Xu J, et al. Enzyme-transporter interplay in the formation and clearance of abundant metabolites of faldaprevir found in excreta but not in circulation. Drug Metab Dispos 2014; 42:384-393.
54. Bertz R. 14th International Workshop on Clinical Pharmacology of HIV Therapy; 24 April 2013; Amsterdam, The Netherlands. Session 5.
55. Sabo J, Kort J, Haschke M, Ballow C, Girlich B, Feifel U, et al. Pharmacokinetic interactions of darunavir/ritonavir, efavirenz, and tenofovir with the hepatitis C virus protease inhibitor faldaprevir in healthy volunteers. 20th CROI, 2013. Oral abstract 35.
56. Kiser JJ, Flexner C. Direct-acting antiviral agents for hepatitis C virus infection. Annu Rev Pharmacol Toxicol 2013; 53:427-449.